What is known and objective: Serotonin-norepinephrine reuptake inhibitors (SNRIs) are commonly used for various psychiatric conditions and neuropathic pain syndromes.
| WHAT IS KNOWN AND OBJECTIVE
Antidepressants are frequently used in the treatment of neuropathic pain where they provide added benefit of ameliorating depressive symptoms. 1 Imipramine was the first antidepressant marketed, marking the breakthrough of tricyclic antidepressants (TCAs) in the 1950s. 2, 3 Their analgesic benefit was first evaluated in the 1960s; however, their mechanism in neuropathic pain was more notably delineated in 1992
by Max and colleagues. 4, 5 Unfortunately, TCAs have significant drawbacks including antagonistic activity at histamine, alpha-1-adrenergic and muscarinic receptors, thereby causing undesired anticholinergic and orthostatic side effects, which limit their use. 5 Pharmaceutical advancements led to the development of selective serotonin reuptake inhibitors (SSRIs) followed by selective serotonin-norepinephrine reuptake inhibitors (SNRIs). SNRIs offer another therapeutic option for neuropathic pain with fewer adverse effects compared to TCAs. 
| Neuropathic pain

| Central pain modulation
The presence of a descending noxious inhibitory control is a generally well-accepted theory. The pathway becomes activated during
The dose required to affect these neurotransmitters, in vitro, depends on the drug's relative binding affinity and selectivity for the transporter.
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| Binding affinity: clinical implications
Affinity indicates how strongly a ligand binds to a receptor and its specificity for the target-binding site vs other receptors or biological off-targets. 17 The lower the Ki for a given receptor, the stronger the binding affinity of the drug to the target receptor. The effectiveness of a ligand to inhibit a molecular target is measured by the half-minimal inhibitor concentration (IC 50 ), which is the concentration required to elicit 50% of the response. For SNRIs, the molecular target would be inhibition of SERT and NET. 17 The selectivity of an antidepressant is the ratio of the relative potency values for each target, which in this case are SERT and NET. 12, 13 Comparative affinities of agents for SERT and NET are listed in Table 1 .
| Venlafaxine
Venlafaxine has approximately 30-fold higher selectivity for 5-HT reuptake inhibition compared to NE reuptake inhibition. Doses of 150 mg/d or higher are required for adequate NE reuptake inhibition. 16, 18 Additionally, doses exceeding 300 mg/d have been shown to inhibit dopamine (DA) reuptake to some extent. 16 Although venlafaxine is not approved by the United States Food and Drug Administration (FDA) for neuropathic pain, it has demonstrated efficacy in diabetic peripheral neuropathy (DPN), which was extrapolated to other neuropathic pain syndromes. [19] [20] [21] In a 6-week randomized placebo-controlled study evaluating venlafaxine extended-release (ER) in the treatment of DPN, venlafaxine ER was superior to placebo at doses of 150-225 mg/d, whereas 75 mg/d was no different from placebo. 21 The authors concluded that the number needed to treat (NNT) for 50% pain intensity reduction with venlafaxine ER 150-225 mg was 4.5 at week 6. Venlafaxine was also studied in neuropathic pain following mastectomy in 13 patients with breast cancer over 10 weeks. 22 There was no significant difference in pain relief compared to placebo, but it is important to note that venlafaxine was studied at 37.5 and 75 mg doses, which were shown to be no different from placebo in previous studies. 21, 22 Venlafaxine has also been evaluated in chemotherapy-induced neuropathy particularly with oxaliplatin and taxanes, but the evidence supporting its efficacy is conflicting. 23, 24 Venlafaxine is metabolized to O-desmethylvenlafaxine through cytochrome P450 (CYP) 2D6, which is more selective for NE compared to the parent drug. 19 be a poor CYP2D6 metabolizer and may have a better response to desvenlafaxine.
| Desvenlafaxine
Desvenlafaxine, the commercially available active metabolite of venlafaxine, is approximately 10 times more selective for inhibiting the reuptake of 5-HT compared to NE. 26 It also has low affinity for muscarinic, cholinergic and alpha-adrenergic receptors in the central nervous system (CNS). Desvenlafaxine is thought to have less anticholinergic side effects compared to venlafaxine, but head-to-head trials are lacking. 27,28 Desvenlafaxine does not carry a FDA-labelled indication for neuropathic pain as the initial clinical trials were not designed to measure efficacy for pain. 25, 27 Improvement in pain scores was observed during these trials but lacked statistical significance. 27 Desvenlafaxine was then studied in a randomized placebo-controlled trial including 412 patients with DPN over 13 weeks, where 200-400 mg doses were found to be superior to placebo. 28 Patients who completed the 13-week trial continued a 9-month open-label flexible-dose extension of the study, which was prematurely terminated for business reasons. 
| Duloxetine
Duloxetine has approximately 10-fold greater selectivity for 5-HT reuptake inhibition over NE reuptake inhibition. 16 Preclinical studies showed some affinity for DA transporters, yet this has not been clini- and a NNT of 8 in fibromyalgia to achieve ≥50% pain reduction over 12 weeks. 31 Duloxetine is metabolized through CYP2D6 and CYP1A2
into inactive metabolites. 13, 30 Smoking, which increases the expression of CYP1A2, was associated with a 30% decrease in duloxetine concentration, compared to non-smoking patients. 32 However, the manufacturer does not recommend dose adjustments in smokers. 
| Milnacipran
Milnacipran is a racemic mixture of two active enantiomers. 33, 34 Milnacipran has almost equal selectivity for 5-HT and NE reuptake inhibition, whereas levomilnacipran has approximately 2-fold greater selectivity for NE over 5-HT. 15, 33, 34 Milnacipran also has mild affinity for inhibiting N-methyl-d-aspartate (NMDA) receptor, which has proposed analgesic effect in neuropathic pain. 35 Milnacipran was studied in fibromyalgia at target doses of 100-200 mg over 8-24 weeks.
Treatment response, defined as 30% pain reduction, was achieved in 40% of participants on milnacipran compared to 30% with placebo, yielding a NNT of 6-10 for additional beneficial outcomes. Withdrawal rates secondary to adverse effects were more common with milnacipran compared to placebo at both the 100 mg (19% of patients in the milnacipran group compared to 12% of patients in the placebo group) and 200 mg dose (24% of patients in the milnacipran group vs 9.5%
of patients in the placebo group, NNH=7). 36 Although only a minority of fibromyalgia patients responded to milnacipran, it was demonstrated that their response was maintained over a period of at least 3 years. 37 Nausea has been commonly reported with milnacipran, possibly related to increased NE, occurring in 37.6% of participants on 200 mg/d, 34.3% with 100 mg/d and 19.2% with placebo in clinical trials. 38 Milnacipran is primarily metabolized through phase II glucuronidation and to a smaller extent through CYP3A4 that accounts for 8% of its metabolism.
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| Levomilnacipran
Levomilnacipran is the levo-enantiomer of milnacipran and is the only SNRI that is more potent for inhibiting NE reuptake over 5-HT. 33 Although levomilnacipran has higher binding affinity to SERT, it actually is more potent at inhibiting the reuptake of NE. Unlike milnacipran, levomilnacipran does not carry an indication for fibromyalgia, as its efficacy has not yet been established. 39 Three phase III placebo-controlled trials were developed to evaluate its efficacy and safety in depression as the primary outcome. [40] [41] [42] Therefore, its use in neuropathic pain in practice has been extrapolated from studies of Value based on rat in vitro transporter assays. Methadone and tramadol exist as a racemic mixture of (R) and (S) enantiomers.
T A B L E 2 Binding affinities (Ki) of selected opioid analgesics its enantiomer milnacipran. Similar to milnacipran, nausea is a com-
